(VIANEWS) – VAN DE VELDE (VAN.BR), AXA (CS.PA), SANOFI (SAN.PA) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio as yet. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. VAN DE VELDE (VAN.BR)
82.16% Payout Ratio
Van de Velde NV, together with its subsidiaries, designs, develops, manufactures, and markets fashionable luxury lingerie and swimwear for women worldwide. It operates through two segments, business to business (B2B) and direct to consumer (D2C). The company offers its products under the PrimaDonna, Marie Jo, Andres Sarda, and Lingerie Styling brands. It also operates retail websites; stores; and boutiques and department stores. The company was founded in 1919 and is headquartered in Schellebelle, Belgium. Van de Velde NV is a subsidiary of Van de Velde Holding NV.
Earnings Per Share
As for profitability, VAN DE VELDE has a trailing twelve months EPS of €2.87.
PE Ratio
VAN DE VELDE has a trailing twelve months price to earnings ratio of 11.46. Meaning, the purchaser of the share is investing €11.46 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.83%.
More news about VAN DE VELDE.
2. AXA (CS.PA)
50.66% Payout Ratio
AXA SA, through its subsidiaries, provides insurance, asset management, and banking services worldwide. The company operates through six segments: France, Europe, Asia, AXA XL, International, and Transversal & Central Holdings. It offers life and savings insurance products, such as savings and retirement, other health, and personal protection products. The company also provides property and casualty insurance products, including car, home, and personal or professional liability to individual and business clients; international insurance for large corporate clients in Europe; and marine and aviation insurance services, as well as property and casualty reinsurance products. In addition, it offers asset management services in the areas of various asset classes, including equities, bonds, hedge funds, private equity, and real estate for the group's insurance companies and their clients, and retail and institutional clients. Further, the company provides health, term life, whole life, universal life, endowment, and other investment-based products for personal/individual and commercial/ group customers. AXA SA was founded in 1852 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, AXA has a trailing twelve months EPS of €2.88.
PE Ratio
AXA has a trailing twelve months price to earnings ratio of 9.58. Meaning, the purchaser of the share is investing €9.58 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.69%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 6, 2022, the estimated forward annual dividend rate is 1.54 and the estimated forward annual dividend yield is 5.44%.
Moving Average
AXA’s value is below its 50-day moving average of €27.60 and way above its 200-day moving average of €24.84.
Revenue Growth
Year-on-year quarterly revenue growth declined by 23.7%, now sitting on 107.73B for the twelve trailing months.
More news about AXA.
3. SANOFI (SAN.PA)
49.31% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €7.22.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 11.97. Meaning, the purchaser of the share is investing €11.97 for every euro of annual earnings.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SANOFI’s EBITDA is 2.63.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.3%, now sitting on 45.7B for the twelve trailing months.
Volume
Today’s last reported volume for SANOFI is 281238 which is 81.23% below its average volume of 1498600.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 3.56 and the estimated forward annual dividend yield is 4.08%.
More news about SANOFI.
4. TUBIZE-FIN (TUB.BR)
43.03% Payout Ratio
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €2.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 31.05. Meaning, the purchaser of the share is investing €31.05 for every euro of annual earnings.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €62.10 at 01:10 EST, under its 52-week low of €62.70.
Moving Average
TUBIZE-FIN’s worth is under its 50-day moving average of €68.52 and way below its 200-day moving average of €72.69.
Volume
Today’s last reported volume for TUBIZE-FIN is 2987 which is 59.23% below its average volume of 7328.
More news about TUBIZE-FIN.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
More news about 1.
